Published : 20 Sep 2021
Another month, and another contract extension. Our Japanese client has extended their contract with Aagami as they have been very satisfied. Aagami have been helping them establish marketing / sales / distribution partnership for the US, China and other markets.
As of today there are 3 term sheet discussions and will move to next steps once our client hears back from the US FDA on their NDA submitted Lidocaine patch. The product has been developed using a proprietary technology platform, and hence not a generic.
The client has also offered Aagami partnering assignment for their other projects and technologies. These are expected to kick-off in January 2022.